Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453742 | 0.91 | MEN1 (0.49) | MEN1KMT2AALDH1A1L3MBTL1KCNA5 | |
| SCHEMBL5446909 | 0.91 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1KCNA5SMN1; SMN2HRH2 | |
| SCHEMBL5447266 | 0.90 | MEN1 (0.50) | MEN1KMT2AALDH1A1L3MBTL1KCNA5 | |
| SCHEMBL5442826 | 0.90 | MEN1 (0.47) | MEN1KMT2AALDH1A1L3MBTL1KCNA5 | |
| SCHEMBL5445213 | 0.89 | NPY1R (0.45) | ALDH1A1SMN1; SMN2HRH3 | |
| SCHEMBL5456550 | 0.87 | MEN1 (0.45) | MEN1KMT2AALDH1A1L3MBTL1KCNA5 | |
| SCHEMBL5446425 | 0.85 | CNR1 (0.40) | KMT2AHRH2HRH3 | |
| SCHEMBL5446902 | 0.85 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1L3MBTL1KCNA5 | |
| SCHEMBL5446531 | 0.84 | NR2F2 (0.48) | MEN1KMT2AALDH1A1L3MBTL1KCNA5 | |
| SCHEMBL14411395 | 0.84 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1L3MBTL1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | MEN1 2039/4885KMT2A 4056/4885ALDH1A1 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.